[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-329910-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-329910-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-novel-approach-for-the-treatment-of-aml-through-ghrh-antagonism-mia-602","A novel approach for the treatment of AML, through GHRH antagonism - MIA-602","","Acute myeloid leukemia (AML) is a highly aggressive, common adult leukemia where chemotherapy and, in some cases, hematopoietic stem cell transplantation remain the gold-standard options. Drug resistance limits effective care for refractory AML, leaving few alternatives beyond palliative measures. This review argues for renewed interest in targeted hormone therapy using growth hormone-releasing hormone (GHRH) antagonism, highlighting pre-clinical evidence supporting anti-cancer activity and potential to address barriers to complete remission.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-novel-approach-for-the-treatment-of-aml-through-ghrh-antagonism-mia-602/329910/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-novel-approach-for-the-treatment-of-aml-through-ghrh-antagonism-mia-602/329910.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is new therapy needed for refractory acute myeloid leukemia (AML)?","Question",{"text":63,"@type":64},"Drug resistance frequently complicates standard AML treatment, leaving limited clinical measures for refractory cases beyond palliative care.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the proposed mechanism in this review?",{"text":68,"@type":64},"The review focuses on targeted hormone therapy using growth hormone-releasing hormone (GHRH) antagonism, aiming to leverage anti-cancer activity in AML models.",{"name":70,"@type":61,"acceptedAnswer":71},"What pre-clinical findings support GHRH antagonists in AML?",{"text":72,"@type":64},"GHRH antagonists show significant anti-cancer effects across experimental human AML cell lines in vitro and in vivo, including drug-resistant leukemic cell line analogs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},329910,1790923757,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","A novel approach for the treatment of AML, through GHRH antagonism: MIA-602  \nJoel Costoya1,2 · Simonetta I. Gaumond1,2 · Ravinder S. Chale8 · Andrew V. Schally3,4,5,6,7 · Joaquin J. Jimenez1,2  \nAccepted: 7 October 2024 / Published online: 17 October 2024 © The Author(s) 2024  \nAbstract  \nAcute myeloid leukemia (AML) is the most aggressive and prevalent form of leukemia in adults. The gold-standard intervention revolves around the use of chemotherapy, and in some cases hematopoietic stem cell transplantation. Drug resistance is a frequent complication resulting from treatment, as it stands there are limited clinical measures available for refractory AML besides palliative care. The goal of this review is to renew interest in a novel targeted hormone therapy in the treatment of AML utilizing growth hormone-releasing hormone (GHRH) antagonism, given it may provide a potential solution for current barriers to achieving complete remission post-therapy. Recapitulating pre-clinical evidence, GHRH antagonists (GHRH-Ant) have significant anti-cancer activity across experimental human AML cell lines in vitro and in vivo and demonstrate significant inhibition of cancer in drug resistant analogs of leukemic cell lines as well. GHRH-Ant act in manners that are orthogonal to anthracyclines and when administered in combination synergize to produce a more potent anti-neoplastic effect. Considering the adversities associated with standard AML therapies and the developing issue of drug resistance, MIA-602 represents a novel approach worth further investigation.  \nKeywords Targeted therapy · Chemotherapy · AML · MIA-602 · Drug-resistance · GHRH antagonism  \nAbbreviations  \n􀀍 Joel Costoya [Jxc2024@miami.edu](Jxc2024@miami.edu)  \n􀀍 Joaquin J. Jimenez [j.jimenez@med.miami.edu](j.jimenez@med.miami.edu)  \n1 Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA  \n2 Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, USA  \n3 Division of Endocrinology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA  \n4 Division of Hematology & Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA  \n5 Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL, USA  \n6 Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, USA  \n7 Department of Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA  \n8 University of Miami Miller School of Medicine, Miami, FL, USA  \nAML  \nAPL  \nPML  \nRARA  \nRARE  \nATRA  \nATO  \nDFS  \nWBC  \nCR  \nGHRH  \nGH  \nIGF-I  \nSVs  \nVIP  \nPCAP  \nEMT  \nGHRH-R  \nAcute Myeloid Leukemia  \nAcute Promyelocytic Leukemia Promyelocytic Leukemia gene Retinoic acid receptor-alpha  \nRetinoic acid response element  \nAll-trans retinoic acid Arsenic trioxide Disease-free Survival White blood cell Complete Remission  \nGrowth hormone-releasing hormone  \nGrowth hormone  \nInsulin-like growth factor 1  \nSplice variants  \nVasoactive intestinal polypeptide  \nPituitary adenylate cyclase-activating polypeptide  \nEpithelial-to-mesenchymal transition Growth hormone-releasing hormone receptor  \n1 Introduction  \nHematopoiesis occurs as higher potency hematopoietic stem cells self-renew and differentiate towards multipotent progenitors, eventually becoming lineage-committed progenitors of the myeloid and lymphoid families. The common myeloid and lymphoid progenitors will undergo subsequent maturation leading to the formation of granulocytes, macrophages, platelets, erythrocytes, and lymphocytes [1] . AMLis a malignancy of hematopoietic origin characterized by recurrent alterations in chromosomal, molecular, and epigenetic programs responsible for the differentiation, survival, and proliferation of myeloid progenitor cells [2] . A distinguishing feature of","cbCaifQQVatsEE0p","https://ap.wps.com/l/cbCaifQQVatsEE0p","pdf",944494,"English","# Abstract\n# Keywords\n## Abbreviations\n# Introduction","[{\"question\":\"Why is new therapy needed for refractory acute myeloid leukemia (AML)?\",\"answer\":\"Drug resistance frequently complicates standard AML treatment, leaving limited clinical measures for refractory cases beyond palliative care.\"},{\"question\":\"What is the proposed mechanism in this review?\",\"answer\":\"The review focuses on targeted hormone therapy using growth hormone-releasing hormone (GHRH) antagonism, aiming to leverage anti-cancer activity in AML models.\"},{\"question\":\"What pre-clinical findings support GHRH antagonists in AML?\",\"answer\":\"GHRH antagonists show significant anti-cancer effects across experimental human AML cell lines in vitro and in vivo, including drug-resistant leukemic cell line analogs.\"}]","A novel approach for the treatment of AML, through GHRH antagonism - MIA-602 | PDF",1789986126,23]